Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Bristol-Myers Squibb Company (BMY) — XLV Health Care · S&P 500 Profile |百時美施貴寶公司介紹

health-careS&P500xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Bristol-Myers Squibb Company (BMY) — Business, History & S&P 500 Profile |百時美施貴寶公司介紹

Bristol-Myers Squibb company profile · oncology, hematology, immunology & cardiovascular medicines · history · financial snapshot · S&P 500 rank #94 · 百時美施貴寶公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 29, 2026 (frozen benchmark)
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$125.40B
Oct 29, 2026 (frozen benchmark)
S&P 500 WEIGHT
0.18%
Rank #94 · Oct 29, 2026 (Slickcharts)
FY2025 TOTAL REVENUES
$48.19B
Essentially flat YoY
FY2025 NET EARNINGS
$7.05B
Operating income $10.00B

SNAPSHOT

TickerBMY (NYSE)
CompanyBristol-Myers Squibb Company
GICS sector / industryHealth Care (XLV) / Pharmaceuticals
S&P 500 rank (by weight)#94 · 0.18% (Oct 29, 2026)
Sector rank (by market cap)#14 in Health Care (Oct 29, 2026)
HeadquartersPrinceton, New Jersey
Founded1887, as Bristol-Myers Company (Squibb founded 1858)
CEOChristopher S. Boerner (chairman and CEO)
Employees≈32,500 (Dec 31, 2025)
Market cap$125.40B (Oct 29, 2026) · price $61.39
SEC filingsEDGAR — CIK 0000014272

WHAT IT DOES

Bristol-Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and sells prescription medicines for serious diseases. It reports as a single segment, concentrated in oncology, hematology, immunology, cardiovascular disease and neuroscience. FY2025 total revenues were $48.19B, essentially flat on FY2024, with 69% from the United States.

Two blockbusters still anchor the top line: Eliquis, the oral anticoagulant co-marketed with Pfizer, at $14.44B, and Opdivo, the immuno-oncology antibody, at $10.05B. Around them, the Growth Portfolio — Reblozyl ($2.33B), Breyanzi ($1.36B), Camzyos ($1.07B), Opdualag ($1.19B) and Cobenfy ($155M in its first full year after approval) — grew 17% to $26.41B, while the Legacy Portfolio fell 15% to $21.79B as Revlimid ($2.95B) continued to lose ground to generics.

The strategy is a race against patent cliffs: replace Eliquis, Opdivo and Revlimid revenue with newer medicines and pipeline assets before exclusivity loss, while funding research from a $10.00B operating profit base. The BioNTech pumitamig collaboration, with a $1.5B upfront payment in 2025, is the largest single bet on that replacement.

BUSINESS SEGMENTS — FY2025 REVENUE BY PORTFOLIO

PortfolioRevenueShareYoY
Growth Portfolio$26.41B54.8%+17%
Legacy Portfolio$21.79B45.2%−15%
Total revenues$48.19B100%Essentially flat
Source: Bristol-Myers Squibb FY2025 Form 10-K (fiscal year ended Dec 31, 2025). The company reports as a single segment; the table splits that segment into its Growth and Legacy portfolios, which sum to total revenues of $48.19B. Displayed figures are rounded; the total is as reported.

HISTORY

1858E. R. Squibb founds Squibb, a maker of pure pharmaceuticals
1887William Bristol and John Myers found Bristol-Myers Company
1989Bristol-Myers and Squibb merge as Bristol-Myers Squibb Company
2012Eliquis (apixaban) wins US FDA approval for stroke prevention in atrial fibrillation
2015Opdivo (nivolumab) wins US FDA approval, anchoring immuno-oncology
2019Closes the Celgene acquisition, adding Revlimid and a hematology pipeline
2020Acquires MyoKardia, adding Camzyos for obstructive hypertrophic cardiomyopathy
2023Announces the Karuna Therapeutics acquisition, adding schizophrenia drug Cobenfy
2024Cobenfy wins US FDA approval for schizophrenia; Karuna deal closes
2025Enters a global BioNTech collaboration on the bispecific antibody pumitamig

COMPETITIVE POSITION

  • Immuno-oncology leadership — Opdivo plus Yervoy and Opdualag give BMS one of the broadest cancer immunotherapy franchises.
  • Cardiovascular scale — Eliquis is the leading oral anticoagulant, co-marketed with Pfizer, and still the largest single product at $14.44B.
  • Growth rotation working — the Growth Portfolio is now 54.8% of revenues, up from a minority share a decade ago, cushioning legacy decline.
  • Cell therapy and neuroscience options — Breyanzi and Abecma in cell therapy, Cobenfy in schizophrenia, diversify beyond oncology.
  • Competition — Merck (Keytruda), AstraZeneca, Johnson & Johnson and Pfizer contest oncology, immunology and cardiovascular; biosimilars and generics attack every maturing brand.

FINANCIAL SNAPSHOT — FY2025

Total revenues$48.19B (essentially flat YoY)
Gross profit$34.26B
Operating income$10.00B
Net earnings attributable to BMS$7.05B
Diluted EPSNot available
Operating cash flow$14.16B
Total assets$90.04B (Dec 31, 2025)
Research and developmentNot available
Source: Bristol-Myers Squibb FY2025 Form 10-K consolidated statements (filed Feb 11, 2026). Diluted EPS is Not available in the verified sources used here and is not estimated.

KEY RISKS

  • Patent cliffs — Eliquis and Opdivo face loss of exclusivity later this decade; the Growth Portfolio must replace roughly $24B of annual sales.
  • Generic erosion — Revlimid has already shown how fast a blockbuster can shrink once generics arrive; the same pattern threatens other maturing brands.
  • Pipeline risk — clinical failures, FDA delays or safety findings can remove a replacement asset at a stroke; pumitamig is unproven at scale.
  • Pricing and policy — US drug-price negotiation, payer pressure and international reference pricing compress realised prices.
  • Debt and deal cost — the Celgene and Karuna deals left a heavy debt load; further large acquisitions would strain the balance sheet.

WHY IT MATTERS FOR THE S&P 500

Bristol-Myers Squibb is the S&P 500’s large-cap biopharma transition story: at a 0.18% index weight and the #14 market cap in Health Care, it is the index’s main exposure to whether a legacy drug maker can rotate to growth products before its blockbusters expire.

Its results track the patent-cliff timetable for the whole sector — Growth Portfolio growth against Legacy decline is the single clearest quarterly read on that rotation.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Oct 29, 2026 crawl)
FinancialsBristol-Myers Squibb FY2025 Form 10-K (SEC EDGAR, filed Feb 11, 2026)
Sector classificationGICS (Pharmaceuticals) via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

BMS

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

代碼BMY(NYSE)
公司Bristol-Myers Squibb Company
GICS 板塊/行業醫療保健(XLV)/製藥
標普500排名(按權重)#94 · 0.18%(2026 年 10 月 29 日)
板塊內排名(按市值)醫療保健第 #14(2026 年 10 月 29 日)
總部美國新澤西州普林斯頓
成立1887 年,Bristol-Myers Company(Squibb 創於 1858 年)
行政總裁Christopher S. Boerner(主席兼行政總裁)
員工≈32,500(2025 年 12 月 31 日)
市值$125.40B(2026 年 10 月 29 日)· 價格 $61.39
SEC 申報EDGAR — CIK 0000014272

業務概覽

百時美施貴寶是一家全球生物製藥公司,研發、生產與銷售治療嚴重疾病的處方藥。公司以單一板塊申報,集中於腫瘤、血液、免疫、心血管與神經科學領域。FY2025 總收入為 $48.19B,與 FY2024 大致持平,其中 69% 來自美國。

兩大重磅藥仍是收入支柱:與輝瑞共同銷售的口服抗凝藥 Eliquis 為 $14.44B,免疫腫瘤抗體 Opdivo 為 $10.05B。圍繞它們,增長組合——Reblozyl($2.33B)、Breyanzi($1.36B)、Camzyos($1.07B)、Opdualag($1.19B)及獲批後首個完整年度的 Cobenfy($155M)——增長 17% 至 $26.41B;傳統組合則下跌 15% 至 $21.79B,Revlimid($2.95B)繼續受仿製藥侵蝕。

策略是一場與專利懸崖賽跑:在 Eliquis、Opdivo 與 Revlimid 失去專利保護前,以新藥與管線資產取代其收入,並以 $10.00B 的營業利潤為研發提供資金。與 BioNTech 就 pumitamig 的合作(2025 年首付款 $1.5B)是這場替代戰中最大的一注。

業務板塊 — FY2025 收入(按組合)

組合收入佔比同比
增長組合$26.41B54.8%+17%
傳統組合$21.79B45.2%−15%
總收入$48.19B100%大致持平
來源:百時美施貴寶 FY2025 Form 10-K(財政年度截至 2025 年 12 月 31 日)。公司以單一板塊申報;本表將該板塊分為增長組合與傳統組合,合計為總收入 $48.19B。數字經四捨五入;總額為申報數。

歷史沿革

1858E. R. Squibb 創立 Squibb,生產純製藥品
1887William Bristol 與 John Myers 創立 Bristol-Myers Company
1989Bristol-Myers 與 Squibb 合併為 Bristol-Myers Squibb Company
2012Eliquis(apixaban)獲美國 FDA 批准用於房顫中風預防
2015Opdivo(nivolumab)獲美國 FDA 批准,奠定免疫腫瘤學地位
2019完成收購 Celgene,取得 Revlimid 與血液學管線
2020收購 MyoKardia,取得阻塞性肥厚型心肌病藥物 Camzyos
2023宣布收購 Karuna Therapeutics,取得精神分裂症藥物 Cobenfy
2024Cobenfy 獲美國 FDA 批准用於精神分裂症;Karuna 交易完成
2025與 BioNTech 達成全球合作,開發雙特異性抗體 pumitamig

競爭地位

  • 免疫腫瘤學領導地位——Opdivo 加 Yervoy 與 Opdualag,構成最廣泛的癌症免疫治療組合之一。
  • 心血管規模——Eliquis 是領先口服抗凝藥,與輝瑞共同銷售,仍是最大單一產品($14.44B)。
  • 增長輪換見效——增長組合現佔收入 54.8%,十年前尚為少數,有助緩衝傳統業務下滑。
  • 細胞治療與神經科學選項——Breyanzi 與 Abecma(細胞治療)、Cobenfy(精神分裂症),令業務不再只依賴腫瘤。
  • 競爭——默克(Keytruda)、阿斯利康、強生與輝瑞爭奪腫瘤、免疫與心血管市場;生物類似藥與仿製藥衝擊每款成熟品牌。

財務快照 — FY2025

總收入$48.19B(同比大致持平)
毛利$34.26B
營業利潤$10.00B
歸屬 BMS 淨利潤$7.05B
攤薄每股盈利Not available
經營現金流$14.16B
總資產$90.04B(2025 年 12 月 31 日)
研發支出Not available
來源:百時美施貴寶 FY2025 Form 10-K 合併報表(2026 年 2 月 11 日申報)。攤薄每股盈利在本稿核實來源中為 Not available,不作估算。

主要風險

  • 專利懸崖——Eliquis 與 Opdivo 將於本十年後期失去專利保護;增長組合須取代約 $24B 的年銷售額。
  • 仿製藥侵蝕——Revlimid 已顯示重磅藥在仿製藥面世後萎縮之快;同一模式威脅其他成熟品牌。
  • 管線風險——臨床失敗、FDA 延誤或安全性發現可一舉除去替代資產;pumitamig 尚未經大規模驗證。
  • 定價與政策——美國藥價談判、支付方壓力與國際參考定價壓縮實際價格。
  • 債務與交易成本——Celgene 與 Karuna 交易留下沉重債務;再作大型收購將令資產負債表承壓。

對標普500的重要性

百時美施貴寶是標普500中的大型生物製藥轉型故事:指數權重 0.18%、醫療保健板塊市值第 #14,是指數對傳統藥廠能否在重磅藥到期前完成增長產品輪換的主要敞口。

其業績追蹤整個行業的專利懸崖時間表——增長組合增長對傳統組合下滑,是這場輪換最清晰的季度讀數。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 29 日抓取)
財務百時美施貴寶 FY2025 Form 10-K(SEC EDGAR,2026 年 2 月 11 日申報)
板塊分類GICS(製藥),據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

BMS

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · BMY
Data as of Oct 29, 2026 · Financials FY2025 (10-K) · Market data Oct 2026
Previous · Medtronic plc (MDT) — XLV Health Care · S&P 500 Profile |美敦力公司介紹Next · Capital One Financial Corporation (COF) — XLF Financials · S&P 500 Profile |第一資本金融公司介紹

Entered 2026-10-30 04:29 · updated 2026-11-14 23:04 · rev 7